Sphera Funds Management LTD. Takes $4.05 Million Position in Arvinas Inc (ARVN)

Share on StockTwits

Sphera Funds Management LTD. bought a new position in shares of Arvinas Inc (NASDAQ:ARVN) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 240,000 shares of the company’s stock, valued at approximately $4,049,000. Sphera Funds Management LTD. owned about 0.75% of Arvinas as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Yale University acquired a new position in shares of Arvinas during the 3rd quarter valued at about $3,114,000. Vivo Capital LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at about $5,061,000. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at about $129,000. Birchview Capital LP acquired a new position in shares of Arvinas during the 3rd quarter valued at about $506,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at about $2,024,000. 41.89% of the stock is currently owned by institutional investors.

In other news, CFO Sean A. Cassidy purchased 1,600 shares of the stock in a transaction dated Monday, October 1st. The shares were purchased at an average price of $16.00 per share, with a total value of $25,600.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bradley Albert Margus bought 40,000 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was bought at an average cost of $16.00 per share, for a total transaction of $640,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 354,100 shares of company stock worth $5,665,600.

Shares of ARVN stock opened at $16.59 on Friday. Arvinas Inc has a twelve month low of $13.70 and a twelve month high of $21.25.

ARVN has been the topic of several recent research reports. Piper Jaffray Companies initiated coverage on shares of Arvinas in a research report on Monday, October 22nd. They set an “overweight” rating and a $23.00 price target on the stock. Citigroup initiated coverage on shares of Arvinas in a research report on Monday, October 22nd. They set a “buy” rating and a $21.00 price target on the stock. Finally, Goldman Sachs Group initiated coverage on shares of Arvinas in a research report on Monday, October 22nd. They set a “neutral” rating and a $17.00 price target on the stock.

WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4001198/sphera-funds-management-ltd-takes-4-05-million-position-in-arvinas-inc-arvn.html.

Arvinas Company Profile

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.

See Also: Quiet Period

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas Inc (NASDAQ:ARVN).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sorrento Therapeutics   Shares Down 5.3%
Sorrento Therapeutics Shares Down 5.3%
COSTAMARE INC/SH  Trading Down 2.9%
COSTAMARE INC/SH Trading Down 2.9%
Onix  Price Hits $0.0005 on Major Exchanges
Onix Price Hits $0.0005 on Major Exchanges
CanonChain  Reaches Market Capitalization of $2.52 Million
CanonChain Reaches Market Capitalization of $2.52 Million
BOXX Token [Blockparty]  Price Reaches $0.0517
BOXX Token [Blockparty] Price Reaches $0.0517
Crystal Token Reaches Market Capitalization of $65,840.00
Crystal Token Reaches Market Capitalization of $65,840.00


Leave a Reply

© 2006-2018 Ticker Report